Key Takeaways
- U.S. and European equity futures slumped as investors priced in an 87% probability of a Federal Reserve interest rate hike following hotter-than-expected August inflation data.
- AstraZeneca (AZN) shares faced pressure after its breast-cancer drug Etcamah failed to meet the primary endpoint in a critical late-stage trial, a major blow to its oncology pipeline.
- OpenAI is reportedly negotiating to conduct AI model training in Australia, seeking to diversify its infrastructure and leverage local partnerships with major employers like Commonwealth Bank.
- China’s top intelligence official issued a rare public warning that rapid AI advances could threaten political stability and critical infrastructure if misused by adversaries.
- Energy security remains a priority in Europe and Asia, with PETRONAS signing a five-year LNG deal with Metlen Energy & Metals (METTK) and Bangladesh seeking alternative U.S. supplies.
Global Markets and Macroeconomic Trends
Global financial markets are on edge as the Federal Reserve prepares for its September policy meeting. U.S. stock futures fell sharply, with Nasdaq-100 futures dropping 1.3% and S&P 500 E-mini futures down 0.5%. This bearish sentiment follows a firm August CPI reading of 3.4%, which has trapped Fed Chairman Kevin Warsh in a "hawkish corner," according to market analysts.
In the currency markets, the EUR/USD fell 0.33% to 1.1549, hitting a near one-month low. The euro is struggling under the weight of a strengthening dollar and concerns that higher energy costs will stifle European growth. Meanwhile, Sweden's August CPIF inflation remained steady at 0.7%, the lowest reading since late 2020, as lower food prices were offset by rising electricity and fuel costs.
AI Expansion and Regulatory Warnings
OpenAI is looking to expand its global footprint, with reports from Nikkei indicating the company is in talks to conduct AI model training in Australia. This move follows a strategic partnership with Australian infrastructure firm Firmus and a skills initiative involving major domestic employers. The expansion aims to lift Australia's productivity while securing the necessary compute resources for next-generation models.
However, the rapid proliferation of AI is drawing scrutiny from global security agencies. China’s Ministry of State Security warned that generative AI could be abused by "hostile forces" to threaten political, institutional, and ideological security. The agency specifically highlighted risks to critical infrastructure and the potential for deepfake technology to undermine social stability.
Healthcare and Energy Sector Developments
AstraZeneca (AZN) reported that its Phase III SERENA-4 trial for the breast-cancer drug Etcamah (camizestrant) did not meet its primary objective of statistically significant improvement in progression-free survival. While the drug showed "numerical improvement" when combined with Pfizer’s Ibrance, the failure to reach statistical significance is a setback for the company’s first-line treatment ambitions in the oncology space.
In the energy sector, Malaysia’s PETRONAS signed a significant LNG supply agreement with Metlen Energy & Metals (METTK). Starting in 2027, PETRONAS will deliver six cargoes per year (approximately 600 million cubic meters annually) to Greece for five years. Simultaneously, Bangladesh is aggressively seeking alternative LNG suppliers, including long-term deals with U.S. providers, to mitigate supply disruptions caused by regional conflicts in the Middle East.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.